Is Milnacipranum [Latin] Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Milnacipranum [Latin]? Is Milnacipranum [Latin] safe for nursing mother and child? Does Milnacipranum [Latin] extracts into breast milk? Does Milnacipranum [Latin] has any long term or short term side effects on infants? Can Milnacipranum [Latin] influence milk supply or can Milnacipranum [Latin] decrease milk supply in lactating mothers?

• DrLact safety Score for Milnacipranum [Latin] is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Milnacipranum [Latin] may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Milnacipranum [Latin] may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Milnacipranum [Latin] .
• It is recommended to evaluate the advantage of not breastfeeding while using Milnacipranum [Latin] Vs not using Milnacipranum [Latin] And continue breastfeeding.
• While using Milnacipranum [Latin] Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Serotonin and Norepinephrine selective re-uptake inhibitor. Authorized for treatment of Fibromyalgia in some countries. Frequent and potential severe side effects have been found. At usual dose it does not induce galactorrhea. Latest update failed to find relevant data on breastfeeding. Pharmacokinetic data (low serum protein binding and high bioavailability) indicates that drug excretion into breast milk in significant amount is highly probable. Absorption by the infant is likely to be high as well. A known alternative would be preferred until more information on the drug is available.

Milnacipranum [Latin] has not been studied in nursing mothers and the manufacturer recommends that nursing mothers not take Milnacipranum [Latin].[1] Because no information is available on the use of Milnacipranum [Latin] during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Galactorrhea is reported by the manufacturer to be a side effect of Milnacipranum [Latin].[1] One woman who was being treated for depression took an intentional overdose of 950 mg of Milnacipranum [Latin] orally. From day 5 to day 15 after the overdose, the patient noted a flow of milk from her left breast. The galactorrhea resolved without treatment.[2] In a study of cases of hyperprolactinemia and its symptoms (e.g., gynecomastia) reported to a French pharmacovigilance center, Milnacipranum [Latin] was not found to have an increased risk of causing hyperprolactinemia compared to other drugs.[3] An observational study looked at outcomes of 2859 women who took an antidepressant during the 2 years prior to pregnancy. Compared to women who did not take an antidepressant during pregnancy, mothers who took an antidepressant during all 3 trimesters of pregnancy were 37% less likely to be breastfeeding upon hospital discharge. Mothers who took an antidepressant only during the third trimester were 75% less likely to be breastfeeding at discharge. Those who took an antidepressant only during the first and second trimesters did not have a reduced likelihood of breastfeeding at discharge.[4] The antidepressants used by the mothers were not specified. A retrospective cohort study of hospital electronic medical records from 2001 to 2008 compared women who had been dispensed an antidepressant during late gestation (n = 575) to those who had a psychiatric illness but did not receive an antidepressant (n = 1552) and mothers who did not have a psychiatric diagnosis (n = 30,535). Women who received an antidepressant were 37% less likely to be breastfeeding at discharge than women without a psychiatric diagnosis, but no less likely to be breastfeeding than untreated mothers with a psychiatric diagnosis.[5] None of the mothers were taking Milnacipranum [Latin].